CAM
ARKG icon

Concorde Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Concorde Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,745
Closed -$205K – 172
2021
Q3 		$205K Sell
2,745
-219
-7% -$18.4K 0.12% 183
2021
Q2 		$275K Buy
2,964
+163
+6% +$13.9K 0.15% 146
2021
Q1 		$249K Buy
+2,801
New +$278K 0.14% 171

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Concorde Asset Management's ARKG Position: Q4 2021 in Review

Concorde Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 2,745 shares — an estimated $205K sold.

Concorde Asset Management first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $275K in Q2 2021. 462 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Concorde Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Concorde Asset Management sold 2,745 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $205K.
  • Concorde Asset Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
  • Concorde Asset Management's ARK Genomic Revolution ETF position peaked at $275K in Q2 2021.
  • 462 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Concorde Asset Management's 13F filing for Q4 2021, filed 2 Feb 2022.